NCT00851643View on ClinicalTrials.gov

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

November 30, 2009

Conditions
Human Papilloma VirusCervical CancerVulvar CancerVaginal CancerGenital Warts
Interventions
BIOLOGICAL

Octavalent HPV with 15 mcg IMX / AAHS

0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

BIOLOGICAL

Octavalent HPV with 30 mcg IMX / AAHS

0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

BIOLOGICAL

Octavalent HPV with 60 mcg IMX / AAHS

0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

BIOLOGICAL

Octavalent HPV with 120 mcg IMX / AAHS

0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

BIOLOGICAL

Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)

0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00851643 - Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) | Biotech Hunter | Biotech Hunter